ARMATA PHARMACEUTICALS, INC. Operating Lease, Weighted Average Discount Rate, Percent
ARMATA PHARMACEUTICALS, INC. (ARMP) had Operating Lease, Weighted Average Discount Rate, Percent of 14.00% as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 14.00%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 14.00%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 14.00%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 14.00%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 14.00% 10-Q · filed 2026-08-12 |
| 2026-03-31 | 14.00% 10-Q · filed 2026-05-13 |
| 2025-12-31 | 14.00% 10-Q · filed 2026-08-12 |
| 2025-09-30 | 14.00% 10-Q · filed 2025-11-12 |
| 2025-06-30 | 13.90% 10-Q · filed 2025-08-12 |
| 2025-03-31 | 13.90% 10-Q · filed 2025-05-14 |
| 2024-12-31 | 13.90% 10-K · filed 2026-03-25 |
| 2024-09-30 | 13.90% 10-Q · filed 2024-11-13 |
| 2024-06-30 | 13.90% 10-Q · filed 2024-08-13 |
| 2024-03-31 | 13.90% 10-Q · filed 2024-05-07 |
| 2023-12-31 | 13.90% 10-K · filed 2025-03-21 |
| 2023-03-31 | 13.90% 10-Q · filed 2024-05-07 |
| 2019-12-31 | 15.00% 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |